Log in

NASDAQ:RDUS - Radius Health Stock Price, Forecast & News

-0.02 (-0.09 %)
(As of 12/15/2019 07:42 AM ET)
Today's Range
Now: $22.38
50-Day Range
MA: $24.60
52-Week Range
Now: $22.38
Volume256,558 shs
Average Volume456,673 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDUS



Sales & Book Value

Annual Sales$99.24 million
Book Value$1.33 per share


Net Income$-221,340,000.00


Market Cap$1.03 billion
Next Earnings Date2/27/2020 (Estimated)

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) released its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.15. The biopharmaceutical company had revenue of $46.77 million for the quarter, compared to analyst estimates of $45.69 million. Radius Health had a negative return on equity of 929.94% and a negative net margin of 98.22%. The firm's revenue for the quarter was up 69.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.09) EPS. View Radius Health's Earnings History.

When is Radius Health's next earnings date?

Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Radius Health.

What price target have analysts set for RDUS?

7 brokerages have issued twelve-month price objectives for Radius Health's stock. Their forecasts range from $27.00 to $43.00. On average, they expect Radius Health's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 56.4% from the stock's current price. View Analyst Price Targets for Radius Health.

What is the consensus analysts' recommendation for Radius Health?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. HC Wainwright analysts commented, "Our $26 price target is based on an 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and $300M peak oral Korsuva sales in Stage 3-5 CKD (the latter even further risk-adjusted to <$100M in our model at 30% probability of success pre-Phase 2). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028. If our DCF valuation with IV Korsuva entirely de-risked (and oral still at 30%), all else equal, would yield a CKD-aP driven valuation of $35/share. That does not yet include any explicit value for Korsuva ex-U.S."" (5/9/2019)
  • 2. According to Zacks Investment Research, "Radius’ lead drug, Tymlos, continues to gain traction. In the first six weeks of 2019, the drug captured a 29% share of the U.S. anabolic osteoporosis market and more than 40% of new anabolic patient starts. Tymlos captured, on average, 20% of the U.S. anabolic osteoporosis market in 2018. In the fourth quarter, the drug’s average U.S. anabolic market share grew to 26% and achieved a 39% share of new anabolic patient starts. However, Radius suffered a setback when the European Commission refused to approve the drug. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded with the presence of drugs like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the past twelve months." (5/6/2019)

Has Radius Health been receiving favorable news coverage?

Media headlines about RDUS stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Radius Health.

Are investors shorting Radius Health?

Radius Health saw a increase in short interest in the month of November. As of November 29th, there was short interest totalling 6,450,000 shares, an increase of 6.1% from the November 14th total of 6,080,000 shares. Based on an average daily volume of 610,200 shares, the days-to-cover ratio is presently 10.6 days. Approximately 14.0% of the company's stock are sold short. View Radius Health's Current Options Chain.

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), NVIDIA (NVDA), Wells Fargo & Co (WFC), Alibaba Group (BABA), Tandem Diabetes Care (TNDM), Ford Motor (F) and Tesla (TSLA).

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.46%), Emerald Advisers LLC (1.96%), Emerald Mutual Fund Advisers Trust (1.65%), Great Lakes Advisors LLC (0.71%), Pictet Asset Management Ltd. (0.69%) and Chicago Equity Partners LLC (0.43%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View Institutional Ownership Trends for Radius Health.

Which major investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Congress Park Capital LLC. Company insiders that have sold Radius Health company stock in the last year include Anthony Rosenberg, Debasish Roychowdhury and Willard H Dere. View Insider Buying and Selling for Radius Health.

Which major investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Rhenman & Partners Asset Management AB, Chicago Equity Partners LLC, Foundry Partners LLC, Pictet Asset Management Ltd., Voloridge Investment Management LLC and Boston Advisors LLC. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $22.38.

How big of a company is Radius Health?

Radius Health has a market capitalization of $1.03 billion and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis. Radius Health employs 398 workers across the globe.View Additional Information About Radius Health.

What is Radius Health's official website?

The official website for Radius Health is http://www.radiuspharm.com/.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

MarketBeat Community Rating for Radius Health (NASDAQ RDUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  478 (Thanks for Voting!)
Underperform Votes:  360 (Thanks for Voting!)
Total Votes:  838
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel